Also known as:CJC + Ipa· community shorthandCJC/Ipa· community shorthand
Growth-hormone axis res…
CJC without DAC + Ipamorelin blend
Evidence levelMixed evidence
Human evidenceNone established
Regulatory statusNo approved medicine identified
What you need to know in 20 seconds
What is it?
Two-peptide GH-axis blend
Research focus
Growth-hormone axis research
Human evidence
Separate human pharmacology exists for related CJC/GHRH compounds and ipamorelin, but no controlled human trial establishing efficacy or safety of the named co-administration blend was identified.
Regulatory status
No approved medicine corresponding to this combination was identified.
Main limitations
Combination synergy, optimal ratio, clinical efficacy, long-term safety or a validated human regimen.
Safety
Endocrine effects, unknown interaction/tolerability at commercial formulations, and identity/purity uncertainty.
i
Separate human pharmacology exists for related CJC/GHRH compounds and ipamorelin, but no controlled human trial establishing efficacy or safety of the named co-administration blend was identified.
What the evidence actually supports
✓Evidence varies by endpoint. See the study records below.
What is not established / key limitations
×Combination synergy, optimal ratio, clinical efficacy, long-term safety or a validated human regimen.
Selected study & evidence records
No structured study detail is currently rendered for this page.
Safety and unknowns
Endocrine effects, unknown interaction/tolerability at commercial formulations, and identity/purity uncertainty.
Endocrine effects, unknown interaction/tolerability at commercial formulations, and identity/purity uncertainty.
Technical details
Mechanism / biologyCombines a short-acting GHRH analogue with a ghrelin-receptor/GH-secretagogue agonist to stimulate GH through complementary pathways.
Route / formulation boundaryComponent studies do not establish the efficacy or safety of the blend.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusDosing research conclusion recorded. No clinical regimen for the exact CJC-without-DAC + ipamorelin blend identified; ipamorelin data alone do not establish the blend dose or ratio.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
